STEVENAGE, England, April 29, 2015 /PRNewswire/ --
Today AKL Research & Development Ltd CEO David Sharples announced that the company was relocating to the UK. "The decision to return to the UK was made as the business environment is increasingly favourable to emerging organisations like AKL," says Sharples.
"A combination of R&D tax credits, the Patent Box tax treatment and the Enterprise Investment Scheme, which will be critical for UK investors in AKL, make for an extremely compelling reason to be UK based."
AKL Research & Development Ltd is an emerging biotech organisation which develops pharmaceuticals for inflammatory conditions which have significant unmet needs via the "clinic-to-lab" development model. AKL develops novel synthetic drugs derived from natural products where anti-inflammatory activity has been observed. This strategy improves the risk profile of tolerability and efficacy.
To date AKL has successfully taken a formulation via this process to a Phase II clinical trial. Currently AKL is researching in the field of degenerative joint disease with a key focus on osteoarthritis and is looking forward to further publications of the pre-clinical in vivo and in vitro data of its lead compound in the coming months. AKL intends to start UK clinical trials in late 2015.
The Company will be based at the Stevenage Bioscience Catalyst, Stevenage, Herts UK. http://www.aklrd.com
AKL Research & Development Ltd will be based in Stevenage Hertfordshire, UK, in the Stevenage Bioscience Catalyst. AKL is an emerging UK biotech company that specialises in developing synthetic versions of natural compounds that have shown activity in inflammatory conditions.
AKL Research & Development, Ltd.
Stevenage Bioscience Catalyst
Gunnels Wood Road
Stevenage, Herts SG1 2FX
+44(0)1438-906797
Company No. 08699350
For further media information please contact
Gill Markham +44(0)7770-827753
For further corporate information please contact
David Miles +44(0)7899-062761
SOURCE AKL Research & Development Ltd
Share this article